✦ LIBER ✦

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B

✍ Scribed by Michael W. Fried; Teerha Piratvisuth; George K. K. Lau; Patrick Marcellin; Wan-Cheng Chow; Graham Cooksley; Kang-Xian Luo; Seung Woon Paik; Yun-Fan Liaw; Peter Button; Matei Popescu

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 414 KB
Volume: 47
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.22065

No coin nor oath required. For personal study only.

✦ Synopsis

The aims of this study were to evaluate the usefulness of quantitative hepatitis B e antigen (HBeAg) values for predicting HBeAg seroconversion in patients treated with peginterferon alfa-2a and to assess the dynamic changes in quantitative HBeAg during therapy, compared with conventional measures of serum hepatitis B virus DNA. Data were analyzed from a large, randomized, multinational phase III registration trial involving 271 HBV-infected HBeAg-positive patients who received peginterferon alfa-2a plus oral placebo for 48 weeks. HBeAg levels were measured serially during therapy using a microparticle enzyme immunoassay validated with in-house reference standards obtained from the Paul Ehrlich Institute (PEIU/mL). In patients who achieved HBeAg seroconversion, levels of HBeAg consistently decreased during treatment and remained at their lowest level during the 24 weeks of posttreatment follow-up. After 24 weeks of treatment, 4% of patients with the highest levels of HBeAg (>100 PEIU/mL) achieved HBeAg seroconversion, yielding a negative predictive value of 96%, which was greater than that obtained for levels of HBV DNA (86%). Late responders to peginterferon alfa-2a could also be differentiated from nonresponders by continued decrease in HBeAg values, which were not evident by changes in HBV DNA. Conclusion: These analyses suggest quantitative HBeAg is a useful adjunctive measurement for predicting HBeAg seroconversion in patients treated with peginterferon when considering both sensitivity and specificity compared with serum HBV DNA.

📜 SIMILAR VOLUMES

Hepatitis B e antigen as a predictor for

Hepatitis B e antigen as a predictor for hepatitis B e antigen–positive chronic hepatitis B patients with peginterferon alfa-2a therapy

✍ En-Qiang Chen; Hong Tang 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB 👁 1 views

PROVE1 trial, 1 in which in the group with an identical treatment schedule, the percentage of patients obtaining SVR with respect to RVR was 75% only. In other words, RVR seems easier to obtain with telaprevir, but less frequently predicts a favorable treatment outcome. A possible explanation might

Long-term lamivudine therapy for childre

Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B

✍ Etienne M. Sokal; Deirdre A. Kelly; Jacek Mizerski; Isabel B. Badia; Jorge A. Ar 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 1 views

One year of lamivudine treatment results in increased hepatitis B e antigen (HBeAg) seroconversion and serum hepatitis B virus (HBV) DNA negativity in children with chronic hepatitis B and high serum alanine aminotransferase concentrations. Two hundred seventy-six children who participated in a 1-ye

HBV DNA suppression in HBeAg-positive ch

HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo

✍ Bettina E. Hansen; Vincent Rijckborst; Martijn J. ter Borg; Prof. Harry L.A. Jan 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB

## Abstract The aim of the present study was to compare the decline of HBV DNA during peginterferon (PEG‐IFN) therapy with spontaneous HBV DNA decline in placebo‐treated patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B. A total of 136 patients who participated in a randomize

Early on-treatment prediction of respons

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

✍ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 1 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.

Serum HBsAg levels during peginterferon

Serum HBsAg levels during peginterferon α-2a treatment with or without thymosin α-1 in HBeAg-positive chronic hepatitis B patients

✍ Eun Young Song; Yunsu Shin; Eun Youn Roh; Shin Sue; Myoung Hee Park; Bo Hyun Kim 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB

## Abstract The importance of serum hepatitis B surface antigen (HBsAg) level as a surrogate marker for viral load and a predictor of treatment response remains unclear. The aim of this study was to investigate whether serum HBsAg correlates with serum hepatitis B virus (HBV) DNA during peginterfer

Prediction of the response to peg-interf

Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment

✍ Bettina E. Hansen; Erik H.C.J. Buster; Ewout W. Steyerberg; Emmanuel Lesaffre; H 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 1 views

## Abstract Peginterferon (PEG‐IFN) results in HBeAg loss combined with virologic response in only a minority of patients with HBeAg positive chronic hepatitis B. Baseline predictors of response to PEG‐IFN include HBV‐genotype, pre‐treatment HBV DNA levels, and ALT. The aims of this study were to d